Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)

Historic Revenue for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to $1.0.

  • Inhibikase Therapeutics' Revenue fell 9999.84% to $1.0 in Q4 2023 from the same period last year, while for Sep 2024 it was $1.0, marking a year-over-year decrease of 9999.97%. This contributed to the annual value of $260501.0 for FY2023, which is 11103.45% up from last year.
  • According to the latest figures from Q4 2023, Inhibikase Therapeutics' Revenue is $1.0, which was down 9999.84% from $79569.0 recorded in Q3 2023.
  • In the past 5 years, Inhibikase Therapeutics' Revenue ranged from a high of $1.4 million in Q1 2021 and a low of $1.0 during Q4 2023
  • Moreover, its 4-year median value for Revenue was $72045.0 (2023), whereas its average is $261438.4.
  • Per our database at Business Quant, Inhibikase Therapeutics' Revenue soared by 316985.6% in 2022 and then plummeted by 9999.84% in 2023.
  • Over the past 4 years, Inhibikase Therapeutics' Revenue (Quarter) stood at $170416.0 in 2020, then tumbled by 98.86% to $1944.0 in 2021, then skyrocketed by 3169.86% to $63566.0 in 2022, then crashed by 100.0% to $1.0 in 2023.
  • Its Revenue stands at $1.0 for Q4 2023, versus $79569.0 for Q3 2023 and $116410.0 for Q2 2023.